{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-011829","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.874696+00:00","generated_at":"2026-05-15T09:27:44.421755+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Lixte Biotechnology raises CEO base salary to $360,000 effective Jan 1, 2026","bullets":["CEO Geordan Pursglove's annual base salary increased from $240,000 to $360,000.","Increase effective retroactively to January 1, 2026; initial payment includes catch-up amount.","Amendment approved by Compensation Committee and Board of Directors on March 18, 2026.","Employee may elect to receive salary in cash or restricted shares based on closing price.","Amendment filed as Exhibit 10.1 to Form 8-K dated March 18, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-011829","json":"https://secwatch.observer/filing/0001493152-26-011829.json","markdown":"https://secwatch.observer/filing/0001493152-26-011829.md","text":"https://secwatch.observer/filing/0001493152-26-011829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226011829/0001493152-26-011829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226011829/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:27:44.421755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}